Leverage Shares Launches 2X Leveraged ETF for Cerebras Systems

Leverage Shares by Themes introduced the CBRG ETF to provide traders with 200% daily exposure to Cerebras Systems following its initial public offering

Justin Tomlinson

Editor-in-Chief, Mora Discover

2 sources
Leverage Shares Launches 2X Leveraged ETF for Cerebras Systems

Leverage Shares by Themes has introduced a new 2X single-stock leveraged ETF, the Leverage Shares 2X Long CBRS Daily ETF, which officially became available for trading on May 15, 2026. Trading under the ticker symbol CBRG, the fund follows the initial public offering of Cerebras Systems. It is specifically designed for active traders who are seeking dynamic ways to engage with high-growth innovators in the technology sector.[1][2]

The new ETF is listed on the Cboe exchange and is tailored to target 200% exposure to the daily performance of its underlying stock, Cerebras Systems, which trades on the NASDAQ under the ticker CBRS. By offering this level of leverage, the fund aims to help both sophisticated traders and retail investors capitalize on market movements. The product is designed to amplify returns, both upward and downward, while providing an efficient tool for participating in the daily performance of the underlying company.[1][2]

Investors utilizing the CBRG ETF will be subject to a management fee of 0.75%. The launch represents a strategic move by Leverage Shares by Themes to provide specialized investment vehicles that allow for amplified participation in the performance of specific high-profile stocks. The firm emphasizes that the product is built for those looking to actively manage their exposure to potentially high-growth market participants.[1][2]

Related stories

Here’s Why Everyone’s Wrong About What’s About to Happen at the Fed
Here’s Why Everyone’s Wrong About What’s About to Happen at the Fed
Investorplace

Here’s Why Everyone’s Wrong About What’s About to Happen at the Fed

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In today's Market 360, I’ll explain the connection between Bessent and Warsh – and why I think it’s good news for investors. I’ll also give you my prediction for the Fed’s next move and how to be positioned before everyone else catches on. The post Here’s Why Everyone’s Wrong About What’s About to Happen at the Fed appeared first on InvestorPlace .

Fiscal policy drives growth
Fiscal policy drives growth
Báo Nhân Dân Điện Tử

Fiscal policy drives growth

Promoting growth will be one of the top priorities in Viet Nam’s economic development and policy planning in 2026. This will contribute to achieving double-digit growth targets in the 2026-2030 period and beyond. An urgent fiscal measure to cool domestic prices PM outlines key tasks, solutions for monetary, fiscal policy management in 2026 2026 state budget: Strengthening fiscal policy to fuel long-term growth

Monopar Therapeutics Reports Q1 2026 Results and Wilson Disease Program Progress
Monopar Therapeutics Reports Q1 2026 Results and Wilson Disease Program Progress
Benzinga

Monopar Therapeutics Reports Q1 2026 Results and Wilson Disease Program Progress

WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ: MNPR ), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates. Recent Program Developments ALXN1840 for Wilson Disease – NDA Submission on Track for Mid-2026 In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at the American Academy of Neurology (AAN) Annual Meeting 2026. The late-breaker oral and poster presentation, titled "Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 F

Synthesized from 3 sources